 |
|
It Is Not Time to Abandon Radiotherapy for Neovascular Age-Related Macular Degeneration
Arch Ophthalmol. 2001;119:275-276.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
THOSE WHO manage patients with neovascular age-related macular degeneration
(AMD) entered the 21st century armed with an effective new treatment: photodynamic
therapy with verteporfin. For a select group of patients, specifically those
with predominantly classic choroidal neovascularization, loss of vision now
can be slowed or halted for at least 2 years. As the evidence in support of
photodynamic therapy has accumulated, so has evidence supporting the lack
of benefit gained from external beam radiotherapy. First put forth by Chakravarthy
et al in 1993,1 external beam radiotherapy
showed no advantage over sham treatment in a randomized clinical trial of
205 patients conducted by the German Radiation Therapy for Age-related Macular
Degeneration (RAD) Study Group.2 In this issue
of the ARCHIVES, Marcus and colleagues3 studied
83 eyes in a double-masked randomized trial and found that vision and anatomic
outcomes were similar in the radiation-treated and sham-treated groups 1 year
after study entry. . . . [Full Text of this Article]
RELATED ARTICLE
External Beam Irradiation of Subfoveal Choroidal Neovascularization Complicating Age-Related Macular Degeneration: One-Year Results of a Prospective, Double-Masked, Randomized Clinical Trial
Dennis M. Marcus, W. Chris Sheils, Maribeth H. Johnson, Sandra B. McIntosh, Diane B. Leibach, Albert Maguire, Judith Alexander, and Chander N. Samy
Arch Ophthalmol. 2001;119(2):171-180.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The association between statin use and age related maculopathy
McGwin et al.
Br. J. Ophthalmol. 2003;87:1121-1125.
ABSTRACT
| FULL TEXT
Age-Related Macular Degeneration
Gottlieb
JAMA 2002;288:2233-2236.
FULL TEXT
|
